Prognostic biomarkers in retroperitoneal dedifferentiated liposarcoma and their clinical impact on patient management.
Ilaria Tortorelli(Istituto Oncologico Veneto), Antonella Brunello(Istituto Oncologico Veneto), Beatrice Valenti(Centro di Riferimento Oncologico), Roberta Maestro(Centro di Riferimento Oncologico), Stefano Basoli(University of Padua), Sara Lonardi(Istituto Oncologico Veneto), Benedetta Chiusole(Istituto Oncologico Veneto), Alessandra Buja(University of Padua), C Palmeri(University of Padua), Marco Rastrelli(Istituti di Ricovero e Cura a Carattere Scientifico), Elena Bellan(University of Padua), Antonio Di Maggio(Istituto Oncologico Veneto), A P Dei Tos(University of Padua), S Vizzaccaro(Istituto Oncologico Veneto), Marta Sbaraglia(University of Padua), Francesco Pierantoni(Istituto Oncologico Veneto)
Cited by 0
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k